Director/PDMR Shareholding

Released : 07.11.2017

RNS Number : 8006V
Allergy Therapeutics PLC
07 November 2017
 

07 November 2017

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Grant of Options under Long Term Incentive Plan

 

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2017, details of which were announced on 5 November 2014, have been met. Consequently, Allergy Therapeutics has today granted to certain employees of the Company, including a PDMR, low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP. Details of the grant of Options to the PDMR are as follows:

 Director

Number of Ordinary Shares over which Options granted

Total number of Ordinary Shares over which Options granted

Total remaining number of Ordinary Shares provisionally  awarded under LTIPs





Manuel Llobet,

Chief Executive Officer

626,399

626,399

1,690,000

 

The Options have been granted in accordance with the LTIP rules with an exercise price of £0.0001 per share, and can be exercised between 07 November 2017 and 06 November 2027.

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Manuel Llobet

2

 

Reason for the notification

Grant of Options

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

ALLERGY THERAPEUTICS PLC

b)

 

LEI

 

 

213800PQ7AHK7KGVOE23

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary Shares of £0.0001 each  

 

 

 

 

GB00B02LCQ05

b)

 

Nature of the transaction

 

 

Grant of Options

c)

 

Price(s) and volume(s)

 

 

 

Exercise Price

 

Volume

£0.0001

626,399

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

 

 

626,399 Options

 

 

£0.001

 

 

e)

 

Date of the transaction

 

 

07 November 2017

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM

 

This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.

 

- ENDS -

 

 

 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Philippa Gardner

allergytherapeutics@consilium-comms.com

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBBBDBXUGBGRR